Results 231 to 240 of about 752,944 (283)

Transient Cyclic Structured Oligonucleotide Designs for Therapeutic Applications

open access: yesCurrent Protocols, Volume 6, Issue 2, February 2026.
Abstract Oligonucleotide‐based therapeutics are now widely used in clinical settings. From the late 1980s to the mid‐1990s, efforts to improve therapeutic efficacy focused on imparting drug‐like properties to oligonucleotides, emphasizing nuclease stability and target sequence affinity.
Sudhir Agrawal
wiley   +1 more source

Noncoding RNAs, Vital Players in Breast Cancer Metastasis. [PDF]

open access: yesBreast Cancer (Dove Med Press)
Kang Y   +5 more
europepmc   +1 more source

Epitranscriptomics as a Candidate Universal Modulator of Dormancy Transitions

open access: yesEcology and Evolution, Volume 16, Issue 2, February 2026.
Dormancy is presented as a conserved, reversible survival program in which epitranscriptomic RNA modifications are proposed to provide a rapid, energy‐efficient layer that establishes, maintains, and terminates the state by modulating mRNA stability, translation, and localization.
Ehsan Pashay Ahi
wiley   +1 more source

The ZNF148‐ZEB1‐AS1‐IGF2BP2‐NOD2 Axis Drives Microglial Antipneumococcal Immunity in Bacterial Meningitis

open access: yesGlia, Volume 74, Issue 2, February 2026.
ZNF148 upregulates ZEB1‐AS1, which scaffolds IGF2BP2 to stabilize NOD2 mRNA, enhancing microglial anti‐pneumococcal immunity via cytokine production and bacterial clearance in bacterial meningitis. ABSTRACT Streptococcus pneumoniae (Spn) meningitis remains a lethal central nervous system (CNS) infection with limited therapies. This study identifies the
Xiufu Hu   +6 more
wiley   +1 more source

Targeting aerobic glycolysis combats tyrosine kinase inhibitor resistance of hepatocellular carcinoma

open access: yesInternational Journal of Cancer, Volume 158, Issue 3, Page 475-487, 1 February 2026.
Abstract Hepatocellular carcinoma (HCC) represents the predominant form of primary liver cancer and is frequently identified at a late stage, necessitating systemic therapy. However, resistance to first‐line tyrosine kinase inhibitor therapies, such as sorafenib and lenvatinib, remains a significant clinical challenge.
Longtao Zhao   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy